by Jeffrey M. Dayno, MD
President and Chief Executive Officer of Harmony Biosciences
Dear FRAXA Community:
As many of you may know, Harmony Biosciences recently completed its acquisition of Zynerba Pharmaceuticals. I am excited for us to progress their work in pursuit of a treatment option for people living with Fragile X syndrome. All of us at Harmony Biosciences are committed to advancing the development and delivery of this innovative treatment, and we are looking forward to supporting the FRAXA Research Foundation (FRAXA) and the Fragile X community. We share FRAXA’s mission of discovering effective treatments and advancing clinical trials that can improve the lives of people living with Fragile X and their families.
It is in this spirit that we are proud to support FRAXA on “Giving Tuesday”, contributing to the power of generosity and providing support for the groundbreaking research funded through FRAXA grants.
“We share FRAXA’s mission of discovering effective treatments and advancing clinical trials that can improve the lives of people living with Fragile X and their families.
It is in this spirit that we are proud to support FRAXA on “Giving Tuesday”, contributing to the power of generosity and providing support for the groundbreaking research funded through FRAXA grants.”
Jeffrey M. Dayno, M.D.
President and Chief Executive Officer
Harmony Biosciences
Harmony Biosciences is a rapidly growing, emerging leader in neurology. We lead with integrity and specialize in developing and delivering innovative treatments for rare neurological diseases. I joined Harmony at the company’s inception, originally as Chief Medical Officer, and was appointed President and Chief Executive Officer earlier this year.
A clinician at heart, I started my career as a practicing neurologist, with more than a decade of experience in clinical and academic medicine. I know what it’s like to sit across from patients and their families in the clinical setting and work with them on a treatment plan. I also personally have seen the impact that developing and delivering innovative treatments can have on patients and their families. While the journey to bring a treatment option to patients can be long and winding, the potential that innovative treatments can have on patients can be profound.
At Harmony, our patient-centric values are at the heart of our company and our nearly 250 team members throughout our organization are steadfast and passionate in our pursuit of developing and commercializing innovative therapies for people with rare neurological diseases who have unmet medical needs.
Over the last six years, Harmony Biosciences has worked to improve the lives of people with narcolepsy and are now focused on building upon that success to bring potential new treatment options to people with Fragile X syndrome, as well as idiopathic hypersomnia, Prader-Willi syndrome, myotonic dystrophy and 22q deletion syndrome.
On behalf of the team at Harmony, we are pleased to support FRAXA on this “Giving Tuesday” and we look forward to connecting with you and being of service to the Fragile X community.
Best regards,
Jeffrey M. Dayno, M.D.
President and Chief Executive Officer
Harmony Biosciences
